The Rheumatology Division of the Medical College of Wisconsin is actively involved with both basic research and clinical studies
One focus where we continue to make great strides is in understanding cartilage biology. Cartilage is certainly a crucial structure within the joints. Damage to the cartilage leads to loss of function and considerable discomfort. We continue to educate future generations of clinical rheumatologists and researchers in the arthritis arena.
The Division of Rheumatology is currently conducting clinical trials in the areas of osteoporosis, osteoarthritis, rheumatoid arthritis, lupus erythematosus, scleroderma and systemic sclerosis. Studies are funded through the pharmaceutical industry or other research institutes including Johns Hopkins and the Hospital for Joint Diseases through a grant from the NIH.
The clinical studies conducted at the Medical College of Wisconsin are exciting and may help people improve the quality of life they lead. Working with other sites as well as with the pharmaceutical industry, we hope to bring these innovative treatments to the public.
Current Clinical Trials
If you would like more information or clarification about any of our ongoing clinical trials, please call Marit Johnson, RN at (414) 955-7022.
Human Genome Sciences and PPD Development
“A Multi-Center, Open Label Continuation Trial of Lympho Stat B Antibody (Monoclonal Anti-BLyS Antibody) in Subjects with Systemic Lupus Erythematosus (SLE) who completes the Phase 2 Protocol LBSL02, Protocol LBSL99.” Enrollment ended but study is ongoing.
(Consortium of Rheumatology Researchers of North America, Inc.) CORRONA
This research initiative is a data registry of patients with inflammatory arthritis. Only patients that are seen in the rheumatology clinic by Dr. M.E. Csuka are currently enrolling and must have the diagnosis of rheumatoid arthritis or psoriatic arthritis.
The purpose of the registry is to understand the natural history of these conditions and to improve the understanding of treatment in clinical practice as opposed to pharmaceutical-sponsored clinical trials. All subjects complete paperwork at their regularly scheduled rheumatology appointments.
The registry collects data on 14,000 patients at 92 sites around the country, making it the largest registry in rheumatology that collects data from both rheumatologists and patients. Particular aspects of the rheumatology specialty, such as the need to treat patients with complex conditions and use a variety of treatment options, make a national database particularly important.